Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC
To evaluate the efficacy and safety of sintilimab and bevacizumab biosimilar combined with pegylated liposomal doxorubicin in pretreated metastatic triple-negative breast cancer
Breast Cancer
DRUG: sintilimab|DRUG: bevacizumab biosimilar|DRUG: pegylated liposomal doxorubicin
PFS, Progression free survival, 6 weeks|OS, Overall Survival, 6 weeks|Adverse Events, Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0, 6 weeks
To evaluate the efficacy and safety of sintilimab and bevacizumab biosimilar combined with pegylated liposomal doxorubicin in pretreated metastatic triple-negative breast cancer